Literature DB >> 11032396

Increased stability of macrophage migration inhibitory factor (MIF) in DU-145 prostate cancer cells.

K Meyer-Siegler1.   

Abstract

Macrophage migration inhibitory factor (MIF) has been localized to the glandular epithelium of the prostate and stimulates the in vitro growth of prostate epithelial cells. [35S]Methionine labeling of MIF protein was used to determine if prostate cells synthesize and secrete this cytokine. The results demonstrated that the DU-145 prostate cancer cells secrete about twice the amount of a more stable protein compared with normal prostate epithelial cells. To investigate if differences in MIF mRNA levels account for the differences in MIF protein secreted by these cells, mRNA stability was analyzed by [3H]uridine incorporation. Following a 12-h pulse, DU-145 cells were found to contain four times the amount of [3H]uridine-labeled MIF mRNA, and this message exhibited a longer half-life than the message found in normal cells (33 h and 19 h, respectively). Nuclear run-on experiments confirmed that the MIF gene is transcribed at a greater rate (1.8-fold) in the DU-145 prostate cancer cells. This study documents, for the first time, that human prostate epithelial cells synthesize and secrete this cytokine. These results indicate that the increased levels of MIF found in prostate cancer cells is likely due to the increased protein and mRNA stability as exhibited by DU-145 cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032396     DOI: 10.1089/10799900050151030

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  11 in total

Review 1.  Janus-faces of NME-oncoprotein interactions.

Authors:  Nikolina Vlatković; Shie-Hong Chang; Mark T Boyd
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-11-01       Impact factor: 3.000

2.  Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors.

Authors:  Yoshihiko Fujita; Rafiqul Islam; Kazuko Sakai; Hiroyasu Kaneda; Kanae Kudo; Daisuke Tamura; Keiichi Aomatsu; Tomoyuki Nagai; Hidekazu Kimura; Kazuko Matsumoto; Marco A de Velasco; Tokuzo Arao; Tadashi Okawara; Kazuto Nishio
Journal:  Invest New Drugs       Date:  2011-09-13       Impact factor: 3.850

3.  Macrophage migration inhibitory factor promotes tumor growth in the context of lung injury and repair.

Authors:  Douglas Arenberg; Tracy R Luckhardt; Shannon Carskadon; Liujian Zhao; Mohammad A Amin; Alisa E Koch
Journal:  Am J Respir Crit Care Med       Date:  2010-06-25       Impact factor: 21.405

4.  The p53-dependent effects of macrophage migration inhibitory factor revealed by gene targeting.

Authors:  G Fingerle-Rowson; O Petrenko; C N Metz; T G Forsthuber; R Mitchell; R Huss; U Moll; W Müller; R Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-23       Impact factor: 11.205

Review 5.  Regulation of the metastasis suppressor Nm23-H1 by tumor viruses.

Authors:  Shuvomoy Banerjee; Hem Chandra Jha; Erle S Robertson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-09-10       Impact factor: 3.000

6.  Expression of MIF and TNFA in psoriatic arthritis: relationship with Th1/Th2/Th17 cytokine profiles and clinical variables.

Authors:  L A Bautista-Herrera; U De la Cruz-Mosso; R Morales-Zambrano; G D Villanueva-Quintero; J Hernández-Bello; M G Ramírez-Dueñas; E Martínez-López; L M Brennan-Bourdon; C J Baños-Hernández; J F Muñoz-Valle
Journal:  Clin Exp Med       Date:  2017-09-30       Impact factor: 3.984

7.  Inhibiting the HSP90 chaperone destabilizes macrophage migration inhibitory factor and thereby inhibits breast tumor progression.

Authors:  Ramona Schulz; Natalia D Marchenko; Lena Holembowski; Günter Fingerle-Rowson; Marina Pesic; Lars Zender; Matthias Dobbelstein; Ute M Moll
Journal:  J Exp Med       Date:  2012-01-23       Impact factor: 14.307

8.  Further evidence for increased macrophage migration inhibitory factor expression in prostate cancer.

Authors:  Katherine L Meyer-Siegler; Kenneth A Iczkowski; Pedro L Vera
Journal:  BMC Cancer       Date:  2005-07-06       Impact factor: 4.430

9.  HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.

Authors:  R Schulz; F Streller; A H Scheel; J Rüschoff; M-C Reinert; M Dobbelstein; N D Marchenko; U M Moll
Journal:  Cell Death Dis       Date:  2014-01-02       Impact factor: 8.469

10.  Restoration of contact inhibition in human glioblastoma cell lines after MIF knockdown.

Authors:  Jörg Schrader; Oliver Deuster; Birgit Rinn; Martina Schulz; Andreas Kautz; Richard Dodel; Bernhard Meyer; Yousef Al-Abed; Karthikeyan Balakrishnan; Jens P Reese; Michael Bacher
Journal:  BMC Cancer       Date:  2009-12-28       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.